<DOC>
	<DOCNO>NCT00550238</DOCNO>
	<brief_summary>To assess long-term safety tolerability ACP-103 subject Parkinson 's disease psychosis .</brief_summary>
	<brief_title>A Study Safety Tolerability Pimavanserin ( ACP-103 ) Patients With Parkinson 's Disease Psychosis</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Pimavanserin</mesh_term>
	<criteria>Subject complete treatment period previous blind study pimavanserin The subject willing able provide consent Caregiver willing able accompany subject visit Subject current evidence serious unstable cardiovascular , respiratory , gastrointestinal , renal , hematologic medical disorder Subject judge Investigator inappropriate study</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Parkinson 's Disease Psychosis</keyword>
</DOC>